Literature DB >> 6628514

Pharmacokinetics and bioavailability of three dyphylline preparations.

J J Stablein, S S Samaan, S C Bukantz, R F Lockey.   

Abstract

The pharmacokinetics and bioavailability of 3 oral dyphylline preparations, solution (S), regular (R) and sustained release (SR), were studied in 8 healthy subjects (mean age 25 years). A single dose of each preparation, 20 mg X kg-1, was given at one week intervals and multiple serum samples obtained over 24 h. Drug levels were measured by high performance liquid chromatography. No adverse effects were found. The dyphylline half-life for the solution was 2.16 +/- 0.18 h and for the tablet 2.59 +/- 0.56 h. The mean clearance rate for S was 13.6 +/- 1.7 h-1 and volume of distribution 43.0 +/- 3.91. Peak concentration (Cmax, micrograms X ml-1), time of peak (Tmax, h), area under the curve (AUC, micrograms X ml-1 X h) and relative bioavailability (RB, %), were determined for three preparations: Cmax S, 33.7 +/- 3.7; R, 27.7 +/- 4.2; SR, 10.4 +/- 1.5 Tmax: S, 0.33 +/- 0.0; R, 0.66 +/- 0.0; SR, 2.13 +/- 1.1 AUC: S, 108.4 +/- 12.1; R, 113.9 +/- 25.2; SR, 104.0 +/- 30.8 RB: Reference Product R, 105.00 +/- 16.00; SR, 100.00 +/- 25.00 The data confirm the short half-life of dyphylline, demonstrate a lack of toxicity for the 20 mg X kg-1 dose and establish bioequivalence for the products studied.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628514     DOI: 10.1007/bf00543805

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  A comparison of the relative toxic, emetic and convulsive actions of a series of methylated xanthine derivatives.

Authors:  J D MCCOLL; J M PARKER; J K FERGUSON
Journal:  J Pharmacol Exp Ther       Date:  1956-03       Impact factor: 4.030

2.  Dihydroxypropyl theophylline; its preparation and pharmacological and clinical study.

Authors:  P V MANEY; J W JONES
Journal:  J Am Pharm Assoc Am Pharm Assoc       Date:  1946-09

3.  Oral aminophylline and dikydroxypropyl theophylline in reversible obstructive airway disease: a single-dose, double-blind, crossover comparison.

Authors:  L D Hudson; M L Tyler; T L Petty
Journal:  Curr Ther Res Clin Exp       Date:  1973-07

4.  An effective oral medication for long term bronchodilation.

Authors:  E R Levine
Journal:  Ann Allergy       Date:  1965-09

5.  Efficacy of dyphylline (dihydroxypropyltheophylline) in exercise-induced bronchospasm.

Authors:  F E Simons; C W Bierman; A C Sprenkle; K J Simons
Journal:  Pediatrics       Date:  1975-11       Impact factor: 7.124

6.  Bioavailability of a sustained-release dyphylline formulation.

Authors:  K J Simons; F E Simons; C W Bierman
Journal:  J Clin Pharmacol       Date:  1977-04       Impact factor: 3.126

7.  Poor absorption of an un-theophylline xanthine bronchodilator.

Authors:  L Hendeles; M Weinberger
Journal:  Am J Hosp Pharm       Date:  1980-02

8.  Pharmacokinetics of orally administered dyphylline.

Authors:  L G Gisclon; J W Ayres; G H Ewing
Journal:  Am J Hosp Pharm       Date:  1979-09

9.  Utilization of intravenous dihydroxypropyl theophylline (dyphylline) in an aminophylline-sensitive patient, and its pharmacokinetic comparison with theophylline.

Authors:  C H Lawyer; E J Bardana; R Rodgers; N Gerber
Journal:  J Allergy Clin Immunol       Date:  1980-05       Impact factor: 10.793

10.  The pharmacokinetics of dihydroxypropyltheophylline: a basis for rational therapy.

Authors:  F E Simons; K J Simons; C W Bierman
Journal:  J Allergy Clin Immunol       Date:  1975-11       Impact factor: 10.793

  10 in total
  2 in total

1.  Zebrafish Embryo as an In Vivo Model for Behavioral and Pharmacological Characterization of Methylxanthine Drugs.

Authors:  Ram Manohar Basnet; Michela Guarienti; Maurizio Memo
Journal:  Int J Mol Sci       Date:  2017-03-09       Impact factor: 5.923

2.  Methylxanthines induce structural and functional alterations of the cardiac system in zebrafish embryos.

Authors:  Ram Manohar Basnet; Daniela Zizioli; Michela Guarienti; Dario Finazzi; Maurizio Memo
Journal:  BMC Pharmacol Toxicol       Date:  2017-11-15       Impact factor: 2.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.